Ordering Recommendation
Use to monitor complement blockage in patients treated with C5 inhibitor drugs.
Mnemonic
C5 INH PAN
Methodology
Quantitative Turbidimetric/Quantitative Radial Immunodiffusion
Performed
Tue, Fri
Reported
1-9 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect
Plain red.
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 2.0 mL serum to an ARUP standard transport tube and freeze immediately. (Min: 2.0 mL)
Storage/Transport Temperature
CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.
Unacceptable Conditions
Specimens received refrigerated, ambient, lipemic specimens, or grossly hemolyzed specimens. Serum separator tubes. Specimens collected using calcium-binding anticoagulants (i.e., EDTA, ACD).
Remarks
Stability
Refer to individual components.
Reference Interval
Test Number |
Components |
Reference Interval |
---|---|---|
Complement Activity, Total Turbidimetric | 38.7-89.9 U/mL | |
Complement Component 5 | 7-20 mg/dL | |
Complement Activity, Alternative Pathway | 59 percent normal or greater | |
Complement C5, Functional | 23.0 U/mL or greater |
Interpretive Data
Component | Interpretation |
---|---|
Complement Activity, Total Turbidimetric | Low: 38.6 U/mL or less Normal: 38.7-89.9 U/mL High: 90.0 U/mL or greater |
Complement C5, Functional | Low: 22.9 U/mL or less Low-Normal: 23.0-28.3 U/mL Normal: 28.4 U/mL or greater |
Complement Activity, Alternative Pathway | This test is intended for screening of functional activity of the alternative pathway of the complement system. Abnormal test results can be due to hereditary absence or acquired functional defect in the activity of any of the individual components of the alternative pathway. |
C5 Inhibitors Drug Monitoring Pan Interp | Patients treated with C5 inhibitors may show decreased/absent activity in total complement functional assay (CH50), alternative pathway functional assay (AH50), and C5 functional assay with normal or elevated C5 protein concentrations. Normal CH50, AH50, or C5 functional activity with normal or elevated C5 protein concentrations indicate inadequate complement blockage. Serial measurements are recommended when monitoring treatment efficacy. Decreases in both C5 concentration and C5 functional activity suggests a secondary consumption process or C5 deficiency. Repeat testing using a new specimen is suggested if in vitro complement activation and consumption of components due to conditions of collection, transport, and/or handling is suspected. |
Compliance Category
Standard
Note
Hotline History
Hotline History
Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
N/A
CPT Codes
86160; 86161 x2; 86162
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
0050156 | Complement Component 5 | 4505-4 |
2005374 | Complement Activity, Alternative Pathway | 74520-8 |
3002576 | Complement Activity, Total Turbidimetric | 4532-8 |
3005962 | Complement C5, Functional | 60472-8 |
3006097 | C5 Inhibitors Drug Monitoring Pan Interp |
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
- AH50
- anti-C5
- C5 inhibitor
- CH50 total
- Complement blocking
- Complement C5
- Complement C5 functional
- Complement monitoring
- concentration
- Eculizumab
- Ravulizumab
C5 Inhibitors Drug Monitoring Panel